Key result
NMES device development for neurorehabilitation involves 6 complex phases according to manufacturer interviews.
Why the study?
The fragmented medical device market limits understanding of how sub-markets navigate development, and despite widespread NMES use, its application for acquired dysarthria treatment has not been sufficiently explored.
This qualitative study outlines the six-phase development process of NMES devices for neurorehabilitation and identifies key barriers and facilitators from the manufacturers' perspective.
Answers are grounded in this paper and cite their sources.
NMES development complexity cautions against rapid clinical translation; leaves open targeted research on manufacturer barriers and facilitators.
PURPOSE: The fragmented nature of the medical device market limits our understanding of how particular sub-markets navigate the device development process. Despite the widespread use of transcutaneous neuromuscular electrical stimulation (NMES), its use for acquired dysarthria treatment has not been sufficiently explored. This study aims to provide a preliminary understanding of the stages involved in the development of NMES devices designed for neurorehabilitation. It also aims to investigate manufacturers' perceptions concerning factors that facilitate or impede its development and determine its applicability for acquired dysarthria. MATERIALS AND METHODS: In-depth semi-structured online interviews were conducted with eight NMES device manufacturers located across Europe, North America and Oceania. The interviews were video-recorded, automatically transcribed, manually reviewed, and analysed using a qualitative content analysis. RESULTS: NMES device development for neurorehabilitation involves six complex phases with sequential and overlapping activities. Some emerging concepts were comparable to established medical device models, while others were specific to NMES. Its adaptability to different neurological disorders, the positive academia-industry collaborations, the industry's growth prospects and the promising global efforts for standardised regulations are all key facilitators for its development. However, financial, political, regulatory, and natural constraints emerged as barriers. Indications and challenges for the applicability of NMES for acquired dysarthria treatment were also discussed. CONCLUSION: The findings provide a foundation for further investigations on the NMES market sub-sector, particularly in the context of neurorehabilitation. The study also provides insights into the potential adoption of NMES for acquired dysarthria, which can serve as a reference for future research.
No takes yet. Share an insight, caveat, or question.
Balzan et al. (2023) studied Acquired dysarthria (n=8). Transcutaneous neuromuscular electrical stimulation (NMES) devices was evaluated on Stages of NMES device development, perceived barriers and facilitators, and applicability for acquired dysarthria. Transcutaneous neuromuscular electrical stimulation (NMES) device development for neurorehabilitation involves 6 complex phases, according to qualitative interviews with 8 manufacturers.
Synapse has enriched 10 related papers. Consider them for comparative context: